FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.
What happened
FDA inspected Green Wave Analytical's San Diego contract testing laboratory from February 15 to March 7, 2022. FDA found that the firm tested drugs, including sterile injectables, without validating methods, with incomplete records and inadequate computer controls, and without proper environmental monitoring for sterility testing, under current good manufacturing practice (CGMP) requirements. For the first three days, the firm denied access to its registered Suite B and falsely said it did not perform CGMP drug testing.
What FDA found
The firm did not validate or verify test methods, including its phenobarbital sodium assay and sterility, endotoxin, and other microbial tests.
21 CFR 211.165(e)Laboratory records lacked key details such as the method used, standards, reagents, sample lot number, and equipment.
21 CFR 211.194(a)HPLC computer systems lacked controls to prevent data deletion or alteration, had no active audit trail, no secure backup, and unvalidated electronic signatures.
21 CFR 211.68(b)The firm did not monitor environmental conditions or personnel for sterility testing and lacked adequate facilities and controls for aseptic testing.
21 CFR 211.42(c)(10)(iv)The quality unit lacked written responsibilities and did not provide effective oversight, and written procedures were not followed.
21 CFR 211.22(a) and (d)The firm denied access to its registered suite for three days and falsely stated it did not perform CGMP drug testing, delaying the inspection.
section 501(j) of the FD&C Act, 21 U.S.C. 351(j)
What FDA wants
Respond in writing within 15 working days with corrective actions and preventive measures; if actions cannot be completed in that time, state the reasons and a completion schedule. Notify FDA before resuming any drug testing at this or another location.
Who should pay attention
- drug manufacturers that use contract testing labs
- sterile injectable drug producers
- quality teams relying on outsourced laboratory data
This is a summary. Read the original letter on fda.gov.